Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
Recruiting
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
11/22/2023
Locations: Quest Research Institute, LLC, Farmington Hills, Michigan
Conditions: Parkinson's Disease
A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80
Recruiting
In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). In this study: Participants will take 225 milligrams (mg) of BIIB122 or a placebo as tablets by mouth. A placebo looks like the study drug but has no real medicine in it. Participants will take BIIB122 or placebo 1 time a day for up to a minimum of 48 weeks and a maximum of 144 weeks. Certain medications for PD will be allowed at enrollment for a subset of part... Read More
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
11/20/2023
Locations: Quest Research Institute, Farmington Hills, Michigan
Conditions: Parkinson Disease
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease
Recruiting
This study investigates the safety and tolerability of drug IkT-148009 in untreated Parkinson's disease volunteers (30 to 80 years old). It also looks at the pharmacokinetics of IkT-148009 in the body and evaluates the effect of IkT-148009 on motor and non-motor features of the disease. This 12 week study is designed to be 3:1 randomized across 3 doses of IkT-148009 or placebo. Each participant will self-administer one of 3 doses or placebo of IkT-148009 once daily (QD) with food for 12 weeks. F... Read More
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
11/17/2023
Locations: Neurology, Farmington Hills, Michigan
Conditions: Parkinson Disease
A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease
Recruiting
This is a multi-center, randomized, double blind, adaptive, parallel-group, placebo controlled Phase 1b study to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics of RO7486967 in participants with idiopathic PD at the early stage of the disease (modified H&Y stage ≤2.5) who are either treatment-naïve or on stable treatment with symptomatic therapy (levodopa and/or pramipexole, ropinirole, rotigotine).
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
11/17/2023
Locations: Quest Research Institute, Farmington Hills, Michigan
Conditions: Parkinson Disease
Early Parkinson's Disease Monotherapy With CVN424
Recruiting
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 compared to placebo in early, untreated Parkinson's Disease (PD) and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
11/16/2023
Locations: Quest Research Institute, Farmington Hills, Michigan
Conditions: Parkinson Disease
Automated Imaging Differentiation of Parkinsonism
Recruiting
The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
11/13/2023
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Parkinson Disease, Multiple System Atrophy, Parkinson Variant, Progressive Supranuclear Palsy
Vestibulopathy, Imbalance, and Gait Disturbances in Parkinson Disease
Recruiting
This study investigates whether vestibular (inner ear) dysfunction is a cause for poor balance in Parkinson Disease (PD), and whether inner ear stimulation with a small device may improve balance. This study will involve clinical testing, brain imaging, and an interventional treatment device for symptoms.
Gender:
All
Ages:
45 years and above
Trial Updated:
11/12/2023
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Parkinson Disease
Vigor and the LDR in Parkinson Disease
Recruiting
Parkinson disease (PD) is a common disorder in which reduced speed of movement results from inadequate brain production of the chemical dopamine. The most effective treatment for PD is the drug levo-dopa, which partially replaces brain dopamine. Despite decades of successful use, how levo-dopa improves speed of movement in PD is not understood. This observational study recruits participants who have been prescribed levo-dopa by their treating physicians. Before their first dose, immediately afte... Read More
Gender:
All
Ages:
Between 45 years and 90 years
Trial Updated:
11/06/2023
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Parkinson Disease
A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants With Parkinson's Disease
Recruiting
The goal of this study is to test KM-819 in halting or slowing the progression of Parkinson's disease. The study evaluates the safety and tolerability of multiple ascending doses of KM-819 in healthy older adults and participants with Parkinson's disease.
Gender:
All
Ages:
40 years and above
Trial Updated:
11/05/2023
Locations: Quest Research Institute, Rose Cancer Center, Royal Oak, Michigan
Conditions: Parkinson Disease
Development of a Multifunctional Rehabilitation Device for Persons With Parkinson's Disease
Recruiting
The researchers have developed a multifunctional rehabilitation device that will be tested in this feasibility trial across three sub-studies: (i) dual session in-lab; (ii) multi-session in-lab and (iii) in the participant's home. A long-term outcome is to test possible benefits of this device (if accepted by the user Parkinson population) on motor and cognitive functions in a clinical trial in a future study. Participants who receive a device during the in-home trial will have the option to kee... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
10/25/2023
Locations: The University of Michigan, Ann Arbor, Michigan
Conditions: Parkinson Disease
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
Recruiting
The objective of this study is to describe disease progression in study participants diagnosed with early Parkinson's Disease or Multiple System Atrophy - Parkinsonian Type up to 18 months as delineated by clinical and biochemical parameters.
Gender:
All
Ages:
Between 35 years and 75 years
Trial Updated:
10/23/2023
Locations: Quest Research Institute, Farmington Hills, Michigan
Conditions: Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
10/20/2023
Locations: Clinical Site, Farmington Hills, Michigan
Conditions: Parkinson Disease